- Home
- CSR vs PRTA Comparison
CSR vs PRTA Comparison
Compare CSR & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- PRTA
- Stock Information
- Founded
- CSR 1970
- PRTA 2012
- Country
- CSR United States
- PRTA Ireland
- Employees
- CSR N/A
- PRTA N/A
- Industry
- CSR Real Estate Investment Trusts
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- PRTA Health Care
- Exchange
- CSR Nasdaq
- PRTA Nasdaq
- Market Cap
- CSR 1.0B
- PRTA 809.8M
- IPO Year
- CSR N/A
- PRTA N/A
- Fundamental
- Price
- CSR $59.02
- PRTA $6.86
- Analyst Decision
- CSR Buy
- PRTA Buy
- Analyst Count
- CSR 8
- PRTA 9
- Target Price
- CSR $71.75
- PRTA $51.71
- AVG Volume (30 Days)
- CSR 98.4K
- PRTA 1.4M
- Earning Date
- CSR 05-01-2025
- PRTA 05-08-2025
- Dividend Yield
- CSR 5.14%
- PRTA N/A
- EPS Growth
- CSR N/A
- PRTA N/A
- EPS
- CSR N/A
- PRTA N/A
- Revenue
- CSR $263,570,000.00
- PRTA $137,935,000.00
- Revenue This Year
- CSR $4.42
- PRTA N/A
- Revenue Next Year
- CSR $3.42
- PRTA $131.71
- P/E Ratio
- CSR N/A
- PRTA N/A
- Revenue Growth
- CSR 2.19
- PRTA 54.55
- 52 Week Low
- CSR $54.13
- PRTA $8.00
- 52 Week High
- CSR $76.16
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- CSR 46.83
- PRTA 25.76
- Support Level
- CSR $59.51
- PRTA $6.92
- Resistance Level
- CSR $62.62
- PRTA $8.08
- Average True Range (ATR)
- CSR 1.67
- PRTA 0.66
- MACD
- CSR 0.12
- PRTA 0.00
- Stochastic Oscillator
- CSR 59.80
- PRTA 15.41
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).